NCT04417998View on ClinicalTrials.gov

Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions
Brain ImagingWhole Body Imaging
Interventions
DRUG

18F-FDG

A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.

DRUG

18F-AV1451

A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.

DEVICE

Siemens E7 Reconstruction Tool

Software to correct for motion

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04417998 - Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction | Biotech Hunter | Biotech Hunter